Mainz Biomed B.V. (MYNZ)
Mainz Biomed B.V. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Mainz, DE. The stock last traded at $3.59, up 0.84% on the session, giving a market capitalisation of $14.7M. On trailing twelve-month figures it carries a trailing P/E of -1.17, a net margin of -3018.3%. Its beta of 0.32 implies it has historically moved less than the broad market.
Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for detecting colorectal cancer. Additionally, they are developing PancAlert, a promising product candidate intended for pancreatic cancer screening. Beyond cancer, Mainz Biomed also provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments. Established in 2008, the company maintains its headquarters in Mainz, Germany.
Mainz Biomed B.V. is most often compared with the following Healthcare names: